Fig. 4
From: CRISPR/Cas9 system: recent applications in immuno-oncology and cancer immunotherapy
CRISPR/Cas9 engineering for adoptive T cell therapy. CRISPR-engineered T cells from either allogeneic or autologous T cells hold the promise to enhance the efficacy and reduce the toxicity of TCR T-cell and CAR T-cell therapy via several mechanisms, including endogenous TCR disruption, TCR and HLA deletion, immunosuppressive factor knock-out, and cytokine modulation. Abbreviations: TAA, tumor-specific antigen; TCR, T cell receptor; CAR, chimeric antigen receptor